Effect of gender, dose, and time on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT)-induced hepatotoxicity in Fischer 344 rats

References

• Alvárez-Sanchez R, Montavon F, Hartung T, Pähler A. Thiazolidinedione bioactivation: A comparison of the bioactivation potentials of troglitazone, rosiglitazone and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry. Chemical Research in Toxicology 2006; 19: 1106–1116
   PubMed Web of Science ®Google Scholar
• Baughman TM, Graham RA, Wells-Knecht K, Silver IS, Tyler LO, Wells-Knecht M, Zhao K. Metabolic activation of pioglitazone identified from rat and human liver microsomes and freshly isolated hepatocytes. Drug Metabolism and Disposition 2005; 33: 733–738
   PubMed Web of Science ®Google Scholar
• Bonkovsky HL, Azar R, Bird S, Szabo G, Banner B. Severe cholestatic hepatitis caused by thiazolidinediones: Risks associated with substituting rosiglitazone for troglitazone. Digestive Diseases and Sciences 2002; 47: 1632–1637
   PubMed Web of Science ®Google Scholar
• Bruno G, Costantino L, Curinga C, Maccari R, Monforte F, Nicolò F, Ottanà R, Vigorita MG. Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorganic and Medicinal Chemistry 2002; 10: 1077–1084
   PubMed Web of Science ®Google Scholar
• Chojkier M. Troglitazone and liver injury: In search of answers. Hepatology 2005; 41: 237–246
   PubMed Web of Science ®Google Scholar
• Cullen JM. Mechanistic classification of liver injury. Toxicologic Pathology 2005; 33: 6–8
   PubMed Web of Science ®Google Scholar
• Czerniak R. Gender-based differences in pharmacokinetics in laboratory animal models. International Journal of Toxicology 2001; 20: 161–163
   PubMed Web of Science ®Google Scholar
• Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Annals of Internal Medicine 2000; 132: 118–121
   PubMed Web of Science ®Google Scholar
• Fujinami A, Ozaki T, Yamamoto T. Antimicrobial activity of 3-phenyloxazolidine-2,4-diones and related compounds. Agricultural and Biological Chemistry 1971; 35: 1707–1719
   Google Scholar
• Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Annals of Internal Medicine 1998; 129: 36–38
   PubMed Web of Science ®Google Scholar
• Gouda HE, Khan A, Schwartz J, Cohen RI. Liver failure in a patient treated with long-term rosiglitazone therapy. American Journal of Medicine 2001; 111: 584–585
   PubMed Web of Science ®Google Scholar
• Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induced liver failure: A case study. American Journal of Medicine 2003; 114: 299–306
   PubMed Web of Science ®Google Scholar
• Hauner H. The mode of action of thiazolidinediones. Diabetes/Metabolism Research and Reviews 2002; 18: S10–S15
   PubMed Web of Science ®Google Scholar
• He K, Talaat RE, Pool WF, Reily MD, Reed JE, Bridges AJ, Woolf TF. Metabolic activation of troglitazone: Identification of a reactive metabolite and mechanisms involved. Drug Metabolism and Disposition 2004; 32: 639–646
   PubMed Web of Science ®Google Scholar
• Hong SK, Anestis DK, Valentovic MA, Ball JG, Brown PI, Rankin GO. Gender differences in the potentiation of N-(3,5-dichlorophenyl)succinimide metabolite nephrotoxicity by phenobarbital. Journal of Toxicology and Environmental Health, Part A 2001; 64: 241–256
   PubMed Web of Science ®Google Scholar
• Hong SK, Anestis DK, Valentovic MA, Ball JG, Brown PI, Wang R-T, Rankin GO. Gender differences in acute N-(3,5-dichlorophenyl)-2-hydroxysuccinimide (NDHS) and N-(3,5-dichlorophenyl)-2-hydroxysuccinamic acid (2-NDHSA) nephrotoxicity in Fischer 344 rats. Journal of Toxicology and Environmental Health, Part A 1998; 54: 613–632
   PubMedGoogle Scholar
• Janakat S, AL-merie H. Optimization of the dose and route of injection, and charaterisation of the time course of carbon tetrachloride-induced hepatotoxicity in the rat. Journal of Pharmacological and Toxicological Methods 2002; 48: 41–44
   PubMed Web of Science ®Google Scholar
• Kassahun K, Pearson PG, Tang W, McIntosh I, Leung K, Elmore C, Dean D, Wang R, Doss G, Baillie TA. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chemical Research in Toxicology 2001; 14: 62–70
   PubMed Web of Science ®Google Scholar
• Kennedy EL, Tchao R, Harvison PJ. Nephrotoxic and hepatotoxic potential of imidazolidinedione-, oxazolidinedione-, and thiazolidinedione-containing analogues of N-(3,5-dichlorophenyl)succinimide (NDPS) in Fischer 344 rats. Toxicology 2003; 186: 79–91
   PubMed Web of Science ®Google Scholar
• Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to the United States Food and Drug Administration. American Journal of Gasteroenterology 2000; 95: 272–276
   PubMed Web of Science ®Google Scholar
• Limaye PB, Apte UM, Shankar K, Bucci TJ, Warbritton A, Mehendale HM. Calpain released from dying hepatocytes mediates progression of acute liver injury induced by model hepatotoxicants. Toxicology and Applied Pharmacology 2003; 191: 211–226
   PubMed Web of Science ®Google Scholar
• Lin G, Cui Y-Y, Liu X-Q. Gender differences in microsomal metabolic activation of hepatotoxic clivorine in rat. Chemical Research in Toxicology 2003; 16: 768–774
   PubMed Web of Science ®Google Scholar
• Lindros KO. Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver. General Pharmacology 1997; 28: 191–196
   PubMedGoogle Scholar
• Maeda K. Hepatocellular injury in a patient receiving pioglitazone. Annals of Internal Medicine 2001; 135: 306
   PubMed Web of Science ®Google Scholar
• Marcy TR, Britton ML, Blevins SM. Second-generation thiazolidinediones and hepatotoxicity. Annals of Pharmacotherapy 2004; 38: 1419–1423
   PubMed Web of Science ®Google Scholar
• Masubuchi Y. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: A review. Drug Metabolism and Pharmacokinetics 2006; 21: 347–356
   PubMed Web of Science ®Google Scholar
• May LD, Lefkowitch JH, Kram MT, Rubin DE. Mixed hepatocellular-cholestatic injury after pioglitazone therapy. Annals of Internal Medicine 2002; 136: 449–452
   PubMed Web of Science ®Google Scholar
• Mugford CA, Kedderis GL. Sex-dependent metabolism of xenobiotics. Drug Metabolism Reviews 1998; 30: 441–498
   PubMed Web of Science ®Google Scholar
• Mulder G. Sex differences in drug conjugation and their consequences for drug toxicity. Sulfation, glucuronidation and glutathione conjugation. Chemico-Biological Interactions 1986; 57: 1–15
   PubMed Web of Science ®Google Scholar
• Nelson SD. Mechanisms of the formation and disposition of reactive metabolites that can cause acute liver injury. Drug Metabolism Reviews 1995; 27: 147–177
   PubMed Web of Science ®Google Scholar
• Ohbayashi H, Sasaki T, Matsumoto M, Noguchi T, Yamazaki K, Aiso S, Nagano K, Arito H, Yamamoto S. Dose- and time-dependent effects of 2,3,7,8-tetrabromodibenzo-p-dioxin on rat liver. Journal of Toxicological Sciences 2007; 32: 47–56
   PubMedGoogle Scholar
• Ong MMK, Latchoumycandane C, Boelsterli UA. Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicological Sciences 2007; 97: 205–213
   PubMed Web of Science ®Google Scholar
• Raheja KL, Linscheer WG, Cho C. Hepatotoxicity and metabolism of acetaminophen in male and female rats. Journal of Toxicology and Environmental Health 1983; 12: 143–158
   PubMed Web of Science ®Google Scholar
• Rakowitz D, Maccari R, Ottanà R, Vigorita MG. In vitro aldose reductase inhibitory activity of 5-benzyl-2,4-thiazolidinediones. Bioorganic and Medicinal Chemistry 2006; 14: 567–574
   PubMed Web of Science ®Google Scholar
• Rankin GO. Nephrotoxicity following acute administration of N-(3,5-dichlorophenyl)succinimide in rats. Toxicology 1982; 23: 21–31
   PubMed Web of Science ®Google Scholar
• Rankin GO. Nephrotoxicity induced by C- and N-arylsuccinimides. Journal of Toxicology and Environmental Health, Part B 2004; 7: 399–416
   PubMed Web of Science ®Google Scholar
• Rankin GO, Cressey-Veneziano K, Brown PI. Onset of and recovery from acute N-(3,5-dichlorophenyl)succinimide-induced nephrotoxicity in Sprague–Dawley rats. Toxicology 1984; 30: 205–216
   PubMed Web of Science ®Google Scholar
• Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D, LeCluyse EL, Sinz MW. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metabolism and Disposition 2003; 31: 439–446
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Hepatotoxicity with thiazolidinediones: Is it a class effect?. Drug Safety 2001; 24: 873–888
   PubMedGoogle Scholar
• Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. New England Journal of Medicine 1998; 338: 861–866
   PubMed Web of Science ®Google Scholar
• Sharyo S, Sagisaka H, Tanak K, Ogata S, Furukawa T, Takaoka M, Manabe S. Troglitazone, pioglitazone and rosiglitazone induce fatty changes in the liver of db/db mice 2001, Toxicologist 60, 349 (abstract no. 1660)
   Google Scholar
• Stine ER, Gunawardhana L, Sipes IG. The acute hepatotoxicity of the isomers of dichlorobenzene in Fischer-344 and Sprague–Dawley rats: Isomer-specific and strain-specific differential toxicity. Toxicology and Applied Pharmacology 1991; 109: 472–481
   PubMed Web of Science ®Google Scholar
• Tettey JN, Maggs JL, Rapeport WG, Primohamed M, Park BK. Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chemical Research in Toxicology 2001; 14: 965–974
   PubMed Web of Science ®Google Scholar
• Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: From orphan receptors to drug discovery. Journal of Medicinal Chemistry 2000; 43: 527–550
   PubMed Web of Science ®Google Scholar